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Abstract 
Introduction: Cetuximab-based chemotherapy showed a statistically significantly higher 
response rate compared with chemotherapy such as FOLFOX. Therefore, FOLFOX plus 
cetuximab is suspected to be the best regimen to alleviate tumor-related symptoms with 
a high response rate.  
Case Report: Here we present the results of 8 consecutive patients with metastatic 
colorectal cancer with poor performance status and/or severe complications who were 
treated with first-line FOLFOX with cetuximab. Six of 8 patients achieved an apparent 
clinical benefit, including radiological response and symptoms improvement. Two 
patients with BRAF mutation could achieve neither clinical benefit nor radiological 
response.  
Conclusion: Although an optimal line of therapy with cetuximab is unclear yet with 
bevacizumab in mind, we propose that patients who need a tumor response to alleviate 
their symptoms due to advanced disease might be candidates for first-line cetuximab-
based therapy as shown in our cases. Additionally, patients with BRAF mutant tumors 
might be important candidates for novel targeted therapy in the future to improve their 
poor prognosis.  
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Introduction 
Cetuximab, a recombinant, human–mouse chimeric monoclonal IgG1 antibody that 
specifically targets the epidermal growth factor receptor (EGFR) has been shown to 
significantly improve the prognosis of metastatic colorectal cancer (MCRC) compared 
with best supportive care alone in the third-line setting [1]. 
Recently, cetuximab was approved as a treatment for MCRC in Japan. Although an 
optimal line of therapy with cetuximab is unclear yet with bevacizumab in mind [2], a 
cetuximab-based regimen showed a statistically significantly higher response rate 
compared with chemotherapy alone [3, 4], in contrast with bevacizumab, which did not 
show an improvement in objective response rate when given in combination with first-
line oxaliplatin with fluoropyrimidine [5]. Therefore, we propose that patients who need a 
tumor response to alleviate their symptoms due to advanced disease might be candidates 
for first-line cetuximab-based therapy. To support this strategy, here we present the 
results of 8 consecutive patients with MCRC with poor performance status and/or severe 
complications who were treated with first-line FOLFOX with cetuximab. 
Case Report 
Between October 2009 and April 2010, 8 patients received FOLFOX pus cetuximab as first-line 
chemotherapy for MCRC (table 1). Eastern Cooperative Oncology Group (ECOG) performance status 
was 1 in 1 patient, 2 in 6 patients, and 3 in 1 patient. Six patients had symptomatic peritoneal 
disseminations with ascites. One patient had a complication of icterus due to severe liver metastases. 
One patient had rectal cancer with anorectal pain due to bone invasion. The primary tumor was present 
in 6 patients. KRAS status was evaluated using cycleave method and was wild type in all patients. All 
patients were treated with the approved dosage and schedule of cetuximab: initially 400 mg/m
2 followed 
by weekly infusions of 250 mg/m
2. The dose of FOLFOX was adjusted individually based on 
performance status or organ dysfunction. The median number of cetuximab administrations was 12 
(range 3–25). Six of 8 patients achieved an apparent clinical benefit, as shown in fig. 1, fig. 2 and table 1. 
In contrast, 2 patients could achieve neither clinical benefit nor radiological response; these 2 patients 
were found to have the BRAF V600 mutation. Grade 3 skin toxicity was observed in 1 patient. Although 
no treatment-related deaths were observed, 1 patient with icterus experienced infection without 
neutropenia. The median survival of all patients was 5.2 months (range 2.5–14+ months). 
Discussion 
Although cetuximab was studied initially in pretreated patients, in contrast with 
bevacizumab [5], the CRYSTAL trial showed a survival benefit of first-line cetuximab, 
especially in patients with KRAS wild-type tumors [3]. In another study that used 
cetuximab with an oxaliplatin-based regimen, the combination showed a higher response 
rate compared with chemotherapy alone [4]. Disappointingly, combination 
chemotherapy of bevacizumab and cetuximab or panitumumab failed to show an 
improvement in efficacy [6, 7]. According to these results, the most recent NCCN 
guideline for the treatment of colon cancer recommended several first-line regimens: 
bevacizumab or cetuximab/panitumumab (KRAS wild type only) combined with 
irinotecan or oxaliplatin with fluoropyrimidines [2]. Since cetuximab or panitumumab is 
also effective even in patients with previous chemotherapy [1, 8], an optimal line of 
therapy with cetuximab or panitumumab is unclear yet with bevacizumab in mind [2]. As 
noted previously, since a cetuximab-based regimen showed a statistically significantly 
higher response rate compared with chemotherapy alone [3, 4], we supposed that patients 
who need a tumor response to alleviate their symptoms might be candidates for first-line  
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cetuximab-based therapy, although the results of an ongoing phase III study comparing 
bevacizumab and cetuximab as first-line chemotherapy are eagerly awaited.  
For patients with poor general status or severe complications, fluoropyrimidine 
monotherapy with or without bevacizumab is recommended according to NCCN 
guidelines [2] and generally selected in clinical practice. However, we suspect that 
FOLFOX plus cetuximab might become an attractive regimen for these patients according 
to our results. Although FOLFOX and FOLFIRI (irinotecan with fluoropyrimidine) is 
considered to be similarly effective as first-line chemotherapy for MCRC, FOLFOX may 
be preferable in patients with severe abdominal symptoms or liver dysfunction as shown 
in our cases since toxicity of irinotecan is frequent in these complicated cases.  
Our results are provocative for the following reasons: first, the regimen of cetuximab 
plus FOLFOX might be feasible, as it had activity in patients with MCRC with poor 
performance status or severe symptoms. In consideration of the risk-benefit balance, 
further investigations will be needed to clarify the distinct indication for either the 
intensive chemotherapy such as FOLFOX plus cetuximab or weak chemotherapy like 
fluoropyrimidine monotherapy for these patients. Second, BRAF might be an important 
negative marker for response to chemotherapy or a strong negative prognostic factor, as 
already reported [9–12]. Although the evaluation of BRAF status prior to treatment with 
an EGFR antibody is still controversial [2], patients with BRAF mutant tumors might be 
important candidates for novel targeted therapy in the future to improve their poor 
prognosis. 
 
 
 
Table 1. Disease characteristics and outcomes of each patient 
  Patient 1  Patient 2  Patient 3  Patient 4  Patient 5  Patient 6  Patient 7  Patient 8 
Age, gender  35, F  60, F  40, M  48, F  68, M  48, F  71, M  74, M 
ECOG PS  3  2  2  1  2  2  2  2 
Metastatic sites  Liver, ovary, 
peritoneum, 
ascites 
Liver, pleural 
effusion 
Peritoneum, 
ascites 
lymph node   Liver,  
peritoneum, 
ascites 
Liver, ovary, 
peritoneum, 
ascites 
Liver,  
peritoneum, 
ascites 
Liver,  
peritoneum, 
ascites 
Complication Abdominal 
distension 
Icterus (T-bil 
5.9 mg/dl) 
Abdominal 
pain 
Rectal pain  Ileus  Abdominal 
distension 
Ileus Abdominal 
distension 
KRAS status* Wild  Wild Wild  Wild  Wild  Wild Wild  Wild 
BRAF status** Wild Wild  Wild Wild Mutant  Wild  Wild Mutant 
Cetuximab admini-
stration (times) 
19 7  25  8  4 12  6  3 
Clinical improvement  Yes  Yes  Yes  Yes  No  Yes  Yes  No 
  PS 1,  
followed by 
colorectomy 
PS1, T-bil  
1.3 mg/dl 
PS1, ascites 
disappeared 
Improved 
pain,  
surgery (R0) 
– PS  1,  ascites 
disappeared, 
surgery 
PS1,  
improved 
intestinal 
obstruction 
– 
Skin toxicity (grade)  2  2  2  2  1  1  1  0 
Survival (months)  14.3+  4.2  10.4  10.3+  2.5  10  5.2  3.5 
F = Female; M = male; ECOG PS = Eastern Cooperative Oncology Group performance status; T-bil = total bilirubin.  
* KRAS codon 12, 13, 61; ** BRAF V600. 
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Fig. 1. a, b CT scans of case 1 before treatment. Multiple liver metastases, massive ascites and ovarian 
metastases are seen. c, d CT scans of case 1 after 4 cycles of FOLFOX plus cetuximab. The multiple liver 
metastases and ovarian metastases were reduced in size, and the ascites had almost disappeared. This 
patient underwent resection of the primary tumor and closure of the colostomy. 
 
 
 
Fig. 2. a, b CT scans of case 3 before treatment. Massive ascites and peritoneum dissemination are 
seen. This case was complicated with abdominal pain and the patient was unable to eat. c, d CT scans 
of case 3 after 4 cycles of FOLFOX plus cetuximab. The ascites had almost disappeared. The 
performance status was improved from 2 to 1 with sufficient oral intake. 
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